Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients.

Background: The efficacy and safety of secukinumab, an interleukin-17 inhibitor, as systemic treatment for patients with moderate-to-severe psoriasis have been demonstrated, but real-world data pertaining to this is limited in China.

Objective: To evaluate the efficacy and safety of secukinumab in clinical practice in Chinese psoriasis patients with or without psoriatic arthritis (PsA) and identify potential baseline factors that affect the response of patients to secukinumab treatment.

Materials & Methods: Data from 81 patients treated with secukinumab for at least 16 weeks were analysed in a retrospective observational study.